Matthias Freiwald
Birkendorfer Str. 65
Biberach An Der Riss, BW 88397, Germany
Biberach An Der Riss, BW 88397, Germany
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 13 publications
Discovery of VU6052959/BI'7927: A Selective mGlu3 Positive Allosteric Modulator (PAM) from an Orthogonal Benzoxazine Chemotype.
Journal: ACS medicinal chemistry letters
Published: June 08, 2026
Discovery of VU6053371/BI03738809: A First-in-Class Selective and CNS-Penetrant mGlu3 Positive Allosteric Modulator (PAM) with Efficacy in a Preclinical Cognition Model.
Journal: ACS chemical neuroscience
Published: June 06, 2026
Exposure-safety analyses of nintedanib in patients with chronic fibrosing interstitial lung disease.
Exposure-safety analyses of nintedanib in patients with chronic fibrosing interstitial lung disease.
Journal: BMC pulmonary medicine
Published: February 24, 2021
Exposure-efficacy analyses of nintedanib in patients with chronic fibrosing interstitial lung disease.
Journal: Respiratory medicine
Published: November 27, 2020
Model-Informed Dose Selection for Xentuzumab, a Dual Insulin-Like Growth Factor-I/II-Neutralizing Antibody.
Journal: Clinical pharmacology and therapeutics
Published: May 08, 2019
Clinical Pharmacokinetics and Pharmacodynamics of Nintedanib.
Journal: Clinical pharmacokinetics
Published: April 25, 2019
Modeling Exposure-Driven Adverse Event Time Courses in Oncology Exemplified by Afatinib.
Journal: CPT: pharmacometrics & systems pharmacology
Published: August 27, 2018
Population pharmacokinetics of nintedanib in patients with idiopathic pulmonary fibrosis.
Journal: Pulmonary pharmacology & therapeutics
Published: October 25, 2017
Population Pharmacokinetics of Volasertib Administered in Patients with Acute Myeloid Leukaemia as a Single Agent or in Combination with Cytarabine.
Journal: Clinical pharmacokinetics
Published: June 21, 2017
Population pharmacokinetics of nintedanib, an inhibitor of tyrosine kinases, in patients with non-small cell lung cancer or idiopathic pulmonary fibrosis.
Journal: Cancer chemotherapy and pharmacology
Published: June 20, 2017
Continued use of afatinib with the addition of cetuximab after progression on afatinib in patients with EGFR mutation-positive non-small-cell lung cancer and acquired resistance to gefitinib or erlotinib.
Journal: Lung cancer (Amsterdam, Netherlands)
Published: March 01, 2017
Clinical Pharmacokinetics and Pharmacodynamics of Afatinib.
Journal: Clinical pharmacokinetics
Published: July 30, 2016
Last Updated: 09/26/2026